{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T09:17:14Z","timestamp":1775639834868,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Russian state-funded project for ICBFM SB RAS","award":["125012900932-4"],"award-info":[{"award-number":["125012900932-4"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"DOI":"10.1007\/s11010-026-05496-z","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T09:32:14Z","timestamp":1771061534000},"page":"1761-1771","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["MiRNA based liquid biopsy for castration-resistant prostate cancer diagnostics"],"prefix":"10.1007","volume":"481","author":[{"given":"Maria Y.","family":"Konoshenko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milena M.","family":"Saitkulova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina V.","family":"Shutko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilya A.","family":"Ostaltsev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel P.","family":"Laktionov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga E.","family":"Bryzgunova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"issue":"3","key":"5496_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"5496_CR2","unstructured":"NCCN Guidelines Version 2 (2022) 11\/30\/21 \u00a9 2021 National Comprehensive Cancer Network\u00ae (NCCN\u00ae)"},{"key":"5496_CR3","unstructured":"Clinical Guidelines of Russian Federation (20.01.2023) in Russian"},{"issue":"2","key":"5496_CR4","doi-asserted-by":"publisher","first-page":"188625","DOI":"10.1016\/j.bbcan.2021.188625","volume":"1876","author":"MY Konoshenko","year":"2021","unstructured":"Konoshenko MY, Bryzgunova OE, Laktionov PP (2021) MiRNAs and androgen deprivation therapy for prostate cancer. Biochim Biophys Acta Rev Cancer 1876(2):188625. https:\/\/doi.org\/10.1016\/j.bbcan.2021.188625","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"5","key":"5496_CR5","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE et al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371(5):424\u2013433. https:\/\/doi.org\/10.1056\/NEJMoa1405095","journal-title":"N Engl J Med"},{"issue":"2","key":"5496_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K et al (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16(2):152\u2013160. https:\/\/doi.org\/10.1016\/S1470-2045(14)71205-7","journal-title":"Lancet Oncol"},{"issue":"3","key":"5496_CR7","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1172\/JCI92099","volume":"127","author":"PS Chen","year":"2017","unstructured":"Chen PS, Su JL, Cha ST et al (2017) miR-107 promotes tumor progression by targeting the let-7 microRNA in mice and humans. J Clin Invest 127(3):1116. https:\/\/doi.org\/10.1172\/JCI92099","journal-title":"J Clin Invest"},{"issue":"1","key":"5496_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41580-018-0045-7","volume":"20","author":"LFR Gebert","year":"2019","unstructured":"Gebert LFR, MacRae IJ (2019) Regulation of MicroRNA function in animals. Nat Rev Mol Cell Biol 20(1):21\u201337. https:\/\/doi.org\/10.1038\/s41580-018-0045-7","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"17","key":"5496_CR9","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1002\/1873-3468.13085","volume":"592","author":"I Ulitsky","year":"2018","unstructured":"Ulitsky I (2018) Interactions between short and long noncoding RNAs. FEBS Lett 592(17):2874\u20132883. https:\/\/doi.org\/10.1002\/1873-3468.13085","journal-title":"FEBS Lett"},{"issue":"4","key":"5496_CR10","doi-asserted-by":"publisher","first-page":"dmm047662","DOI":"10.1242\/dmm.047662","volume":"14","author":"M Hill","year":"2021","unstructured":"Hill M, Tran N (2021) MiRNA interplay: mechanisms and consequences in cancer. Dis Model Mech 14(4):dmm047662. https:\/\/doi.org\/10.1242\/dmm.047662","journal-title":"Dis Model Mech"},{"issue":"4","key":"5496_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0215003","volume":"14","author":"OE Bryzgunova","year":"2019","unstructured":"Bryzgunova OE, Zaporozhchenko IA, Lekchnov EA et al (2019) Data analysis algorithm for the development of extracellular miRNA-based diagnostic systems for prostate cancer. PLoS One 14(4):e0215003. https:\/\/doi.org\/10.1371\/journal.pone.0215003","journal-title":"PLoS One"},{"issue":"1","key":"5496_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10010038","volume":"10","author":"MY Konoshenko","year":"2020","unstructured":"Konoshenko MY, Lekchnov EA, Bryzgunova OE et al (2020) The panel of 12 cell-free microRNAs as potential biomarkers in prostate neoplasms. Diagnostics 10(1):38. https:\/\/doi.org\/10.3390\/diagnostics10010038","journal-title":"Diagnostics"},{"issue":"12","key":"5496_CR13","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1111\/iju.15043","volume":"29","author":"F Urabe","year":"2022","unstructured":"Urabe F, Yamamoto Y, Kimura T (2022) MiRNAs in prostate cancer: intercellular and extracellular communications. Int J Urol 29(12):1429\u20131438. https:\/\/doi.org\/10.1111\/iju.15043","journal-title":"Int J Urol"},{"issue":"1","key":"5496_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.eururo.2014.08.067","volume":"67","author":"BS Haflidad\u00f3ttir","year":"2015","unstructured":"Haflidad\u00f3ttir BS, Ceder Y (2015) Exosomal microRNAs as potential biomarkers in castration-resistant prostate cancer. Eur Urol 67(1):42\u201343. https:\/\/doi.org\/10.1016\/j.eururo.2014.08.067","journal-title":"Eur Urol"},{"issue":"9","key":"5496_CR15","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1517\/14728222.2016.1162294","volume":"20","author":"MJ Chalanqui","year":"2016","unstructured":"Chalanqui MJ, O\u2019Doherty M, Dunne NJ, McCarthy HO (2016) MiRNA 34a: a therapeutic target for castration-resistant prostate cancer. Expert Opin Ther Targets 20(9):1075\u20131085. https:\/\/doi.org\/10.1517\/14728222.2016.1162294","journal-title":"Expert Opin Ther Targets"},{"issue":"11","key":"5496_CR16","doi-asserted-by":"publisher","first-page":"4252","DOI":"10.1111\/cas.15948","volume":"114","author":"W Wang","year":"2023","unstructured":"Wang W, Kong P, Feng K et al (2023) Exosomal miR-222-3p contributes to castration-resistant prostate cancer by activating mTOR signaling. Cancer Sci 114(11):4252\u20134269. https:\/\/doi.org\/10.1111\/cas.15948","journal-title":"Cancer Sci"},{"issue":"11","key":"5496_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16111347","volume":"16","author":"M Ferreira","year":"2024","unstructured":"Ferreira M, Morais M, Medeiros R, Teixeira AL (2024) MicroRNAs as promising therapeutic agents against prostate cancer resistant to castration-where are we now? Pharmaceutics 16(11):1347. https:\/\/doi.org\/10.3390\/pharmaceutics16111347","journal-title":"Pharmaceutics"},{"issue":"3","key":"5496_CR18","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-24-0274","volume":"32","author":"J Lyman","year":"2025","unstructured":"Lyman J, Dehm SM (2025) Systems-level liquid biopsy in advanced prostate cancer. Endocr Relat Cancer 32(3):e240274. https:\/\/doi.org\/10.1530\/ERC-24-0274","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"5496_CR19","doi-asserted-by":"publisher","first-page":"0009","DOI":"10.55092\/exrna20240009","volume":"6","author":"O Bryzgunova","year":"2024","unstructured":"Bryzgunova O, Yakovlev A, Ostaltsev I et al (2024) Looking for MiRNA from plasma microvesicles differentially expressed in prostate tumors and healthy men. ExRNA 6(2):0009. https:\/\/doi.org\/10.55092\/exrna20240009","journal-title":"ExRNA"},{"issue":"12","key":"5496_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19124088","volume":"19","author":"EA Lekchnov","year":"2018","unstructured":"Lekchnov EA, Amelina EV, Bryzgunova OE et al (2018) Searching for the novel specific predictors of prostate cancer in urine: the analysis of 84 miRNA expression. Int J Mol Sci 19(12):4088. https:\/\/doi.org\/10.3390\/ijms19124088","journal-title":"Int J Mol Sci"},{"issue":"3","key":"5496_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11030384","volume":"11","author":"MY Konoshenko","year":"2021","unstructured":"Konoshenko MY, Lekchnov EA, Bryzgunova OE et al (2021) Isolation of extracellular vesicles from biological fluids via the aggregation-precipitation approach for downstream miRNAs detection. Diagnostics 11(3):384. https:\/\/doi.org\/10.3390\/diagnostics11030384","journal-title":"Diagnostics"},{"key":"5496_CR22","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ab.2016.01.025","volume":"499","author":"EA Lekchnov","year":"2016","unstructured":"Lekchnov EA, Zaporozhchenko IA, Morozkin ES et al (2016) Protocol for miRNA isolation from biofluids. Anal Biochem 499:78\u201384. https:\/\/doi.org\/10.1016\/j.ab.2016.01.025","journal-title":"Anal Biochem"},{"issue":"9","key":"5496_CR23","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1073\/pnas.1100048108","volume":"108","author":"M Boeri","year":"2011","unstructured":"Boeri M, Verri C, Conte D et al (2011) MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A 108(9):3713\u20133718. https:\/\/doi.org\/10.1073\/pnas.1100048108","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5496_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-015-0820-9","volume":"16","author":"E Landoni","year":"2015","unstructured":"Landoni E, Miceli R, Callari M et al (2015) Proposal of supervised data analysis strategy of plasma miRNAs from hybridisation array data with an application to assess hemolysis-related deregulation. BMC Bioinformatics 16:388. https:\/\/doi.org\/10.1186\/s12859-015-0820-9","journal-title":"BMC Bioinformatics"},{"issue":"5","key":"5496_CR25","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/14737167.2017.1375855","volume":"17","author":"A Dellis","year":"2017","unstructured":"Dellis A, Papatsoris A (2017) Therapeutic outcomes of the LHRH antagonists. Expert Rev Pharmacoecon Outcomes Res 17(5):481\u2013488. https:\/\/doi.org\/10.1080\/14737167.2017.1375855","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"2","key":"5496_CR26","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0022-5347(05)65973-3","volume":"166","author":"AC Spetz","year":"2001","unstructured":"Spetz AC, Hammar M, Lindberg B, Sp\u00e5ngberg A, Varenhorst E (2001) Scandinavian prostatic cancer Group-5 trial Study. Prospective evaluation of hot flashes during treatment with parenteral Estrogen or complete androgen ablation for metastatic carcinoma of the prostate. J Urol 166(2):517\u2013520","journal-title":"J Urol"},{"issue":"3","key":"5496_CR27","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.urology.2008.09.013","volume":"73","author":"H Sakai","year":"2009","unstructured":"Sakai H, Igawa T, Tsurusaki T et al (2009) Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer. Urology 73(3):635\u2013640. https:\/\/doi.org\/10.1016\/j.urology.2008.09.013","journal-title":"Urology"},{"issue":"1","key":"5496_CR28","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2217\/fon.14.145","volume":"11","author":"M Tucci","year":"2015","unstructured":"Tucci M, Scagliotti GV, Vignani F (2015) Metastatic castration-resistant prostate cancer: time for innovation. Future Oncol 11(1):91\u2013106. https:\/\/doi.org\/10.2217\/fon.14.145","journal-title":"Future Oncol"},{"issue":"10","key":"5496_CR29","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.ctrv.2015.08.002","volume":"41","author":"C Buttigliero","year":"2015","unstructured":"Buttigliero C, Tucci M, Bertaglia V et al (2015) Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. Cancer Treat Rev 41(10):884\u2013892. https:\/\/doi.org\/10.1016\/j.ctrv.2015.08.002","journal-title":"Cancer Treat Rev"},{"key":"5496_CR30","doi-asserted-by":"publisher","unstructured":"Saranyutanon S, Srivastava SK, Pai S, Singh S, Singh AP (2019). Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope. Cancers (Basel). 12(1):51. https:\/\/doi.org\/10.3390\/cancers12010051","DOI":"10.3390\/cancers12010051"},{"issue":"4","key":"5496_CR31","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1158\/1940-6207.CAPR-23-0156","volume":"17","author":"S Alimena","year":"2024","unstructured":"Alimena S, Stephenson BJK, Webber JW et al (2024) Differences in serum miRNA profiles by race, ethnicity, and socioeconomic status: implications for developing an equitable ovarian cancer screening test. Cancer Prev Res (Phila) 17(4):177\u2013185. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-23-0156","journal-title":"Cancer Prev Res (Phila)"},{"issue":"1","key":"5496_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12896-021-00706-6","volume":"21","author":"HP Roest","year":"2021","unstructured":"Roest HP, IJzermans JNM, van der Laan LJW (2021) Evaluation of RNA isolation methods for microRNA quantification in a range of clinical biofluids. BMC Biotechnol 21(1):48. https:\/\/doi.org\/10.1186\/s12896-021-00706-6","journal-title":"BMC Biotechnol"},{"issue":"4","key":"5496_CR33","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/acel.12484","volume":"15","author":"S Weilner","year":"2016","unstructured":"Weilner S, Schraml E, Wieser M et al (2016) Secreted microvesicular miR-31 inhibits osteogenic differentiation of mesenchymal stem cells. Aging Cell 15(4):744\u201354. https:\/\/doi.org\/10.1111\/acel.12484","journal-title":"Aging Cell"},{"issue":"10","key":"5496_CR34","doi-asserted-by":"publisher","first-page":"361","DOI":"10.20452\/pamw.1093","volume":"121","author":"T Staszel","year":"2011","unstructured":"Staszel T, Zapa\u0142a B, Polus A et al (2011) Role of MicroRNAs in endothelial cell pathophysiology. Pol Arch Med Wewn 121(10):361\u2013366 PMID: 21946298","journal-title":"Pol Arch Med Wewn"},{"issue":"1","key":"5496_CR35","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1159\/000374062","volume":"36","author":"Y Wang","year":"2015","unstructured":"Wang Y, Men M, Yang W et al (2015) MiR-31 downregulation protects against cardiac ischemia\/reperfusion injury by targeting protein kinase C epsilon (PKC\u03b5) directly. Cell Physiol Biochem 36(1):179\u201390. https:\/\/doi.org\/10.1159\/000374062","journal-title":"Cell Physiol Biochem"},{"issue":"45","key":"5496_CR36","doi-asserted-by":"publisher","first-page":"73739","DOI":"10.18632\/oncotarget.12061","volume":"7","author":"R Ottman","year":"2016","unstructured":"Ottman R, Levy J, Grizzle WE, Chakrabarti R (2016) The other face of miR-17-92a cluster, exhibiting tumor suppressor effects in prostate cancer. Oncotarget 7(45):73739\u201373753. https:\/\/doi.org\/10.18632\/oncotarget.12061","journal-title":"Oncotarget"},{"issue":"1","key":"5496_CR37","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12943-017-0726-4","volume":"16","author":"M Rodr\u00edguez","year":"2017","unstructured":"Rodr\u00edguez M, Bajo-Santos C, Hessvik NP et al (2017) Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes. Mol Cancer 16(1):156. https:\/\/doi.org\/10.1186\/s12943-017-0726-4","journal-title":"Mol Cancer"},{"key":"5496_CR38","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s12975-014-0364-8","volume":"5","author":"SS S\u00f8rensen","year":"2014","unstructured":"S\u00f8rensen SS, Nygaard AB, Nielsen MY et al (2014) miRNA expression profiles in cerebrospinal fluid and blood of patients with acute ischemic stroke. Transl Stroke Res 5:711\u2013718. https:\/\/doi.org\/10.1007\/s12975-014-0364-8","journal-title":"Transl Stroke Res"},{"issue":"4","key":"5496_CR39","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.3906\/sag-2010-183","volume":"51","author":"S Hasano\u011flu","year":"2021","unstructured":"Hasano\u011flu S, G\u00f6nc\u00fc B, Y\u00fccesan E et al (2021) Investigating differential miRNA expression profiling using serum and urine specimens for detecting potential biomarkers for early prostate cancer diagnosis. Turk J Med Sci 51(4):1764\u20131774. https:\/\/doi.org\/10.3906\/sag-2010-183","journal-title":"Turk J Med Sci"},{"issue":"6","key":"5496_CR40","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/bjc.2016.233","volume":"115","author":"K Stuopelyte","year":"2016","unstructured":"Stuopelyte K, Daniunaite K, Bakavicius A et al (2016) The utility of urine-circulating miRNAs for detection of prostate cancer. Br J Cancer 115(6):707\u2013715. https:\/\/doi.org\/10.1038\/bjc.2016.233","journal-title":"Br J Cancer"},{"issue":"8","key":"5496_CR41","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/s12276-022-00837-6","volume":"54","author":"J Gan","year":"2022","unstructured":"Gan J, Liu S, Zhang Y et al (2022) MicroRNA-375 is a therapeutic target for castration-resistant prostate cancer through the PTPN4\/STAT3 axis. Exp Mol Med 54(8):1290\u20131305. https:\/\/doi.org\/10.1038\/s12276-022-00837-6","journal-title":"Exp Mol Med"},{"issue":"4","key":"5496_CR42","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/pros.22572","volume":"73","author":"HC Nguyen","year":"2013","unstructured":"Nguyen HC, Xie W, Yang M et al (2013) Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate 73(4):346\u2013354. https:\/\/doi.org\/10.1002\/pros.22572","journal-title":"Prostate"},{"issue":"1","key":"5496_CR43","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/pros.22545","volume":"73","author":"S Lehmusvaara","year":"2013","unstructured":"Lehmusvaara S, Erkkil\u00e4 T, Urbanucci A et al (2013) Goserelin and bicalutamide treatments alter the expression of microRNAs in the prostate. Prostate 73(1):101\u2013112. https:\/\/doi.org\/10.1002\/pros.22545","journal-title":"Prostate"},{"issue":"5","key":"5496_CR44","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/j.celrep.2018.10.014","volume":"25","author":"PM Godoy","year":"2018","unstructured":"Godoy PM, Bhakta NR, Barczak AJ et al (2018) Large differences in small RNA composition between human biofluids. Cell Rep 25(5):1346\u20131358. https:\/\/doi.org\/10.1016\/j.celrep.2018.10.014","journal-title":"Cell Rep"},{"key":"5496_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110703","volume":"131","author":"M Taheri","year":"2020","unstructured":"Taheri M, Shirvani-Farsani Z, Ghafouri-Fard S, Omrani MD (2020) Expression profile of microRNAs in bladder cancer and their application as biomarkers. Biomed Pharmacother 131:110703. https:\/\/doi.org\/10.1016\/j.biopha.2020.110703","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"5496_CR46","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.bbrc.2020.02.098","volume":"525","author":"Z Ma","year":"2020","unstructured":"Ma Z, Chao F, Wang S et al (2020) CTHRC1 affects malignant tumor cell behavior and is regulated by miR-30e-5p in human prostate cancer. Biochem Biophys Res Commun 525(2):418\u2013424. https:\/\/doi.org\/10.1016\/j.bbrc.2020.02.098","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"5496_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031285","volume":"23","author":"G Furesi","year":"2022","unstructured":"Furesi G, de Jesus Domingues AM, Alexopoulou D et al (2022) Exosomal miRNAs from prostate cancer impair osteoblast function in mice. Int J Mol Sci 23(3):1285. https:\/\/doi.org\/10.3390\/ijms23031285","journal-title":"Int J Mol Sci"},{"issue":"40","key":"5496_CR48","doi-asserted-by":"publisher","first-page":"67626","DOI":"10.18632\/oncotarget.18795","volume":"8","author":"SM Egan","year":"2017","unstructured":"Egan SM, Karasik E, Ellis L, Gollnick SO (2017) MiR-30e* is overexpressed in prostate cancer and promotes NF-\u03baB-mediated proliferation and tumor growth. Oncotarget 8(40):67626\u201367638. https:\/\/doi.org\/10.18632\/oncotarget.18795","journal-title":"Oncotarget"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05496-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-026-05496-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05496-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T08:40:40Z","timestamp":1775637640000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-026-05496-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":48,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["5496"],"URL":"https:\/\/doi.org\/10.1007\/s11010-026-05496-z","relation":{},"ISSN":["1573-4919"],"issn-type":[{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the ethics committee of ICBFM SB RAS (\u211610, 22.12.2008).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}